Market News & Trends
Nemera’s e-Novelia® Ophthalmic Add-On Wins “Excellence in Pharma: Drug Delivery Devices” Award
A team of industry experts awarded Nemera’s electronic add-on for ophthalmic droppers with a prestigious CPhI Award for Best Drug Delivery Device in its category.
mCig Announces Topical Pain Relief Formulations
mCig Inc. recently announce that its laboratory in Europe is close to completion of new CBD-infused topical line. mCig plans to use its producer, processor and…
Melt Pharmaceuticals Initiates Clinical Development Program
Melt Pharmaceuticals recently announced that following the presentation of clinical data on the MKO Melt (midazolam/ketamine/ondansetron) from a 611-patient IRB approved prospective, controlled, randomized, three…
Polyganics Initiates First-in-Human Trial of LIQOSEAL
Polyganics recently announced that it has initiated enrollment of patients into a first-in-human clinical trial of LIQOSEAL, its dura sealant patch. The self-adhesive patch has…
Athenex Presents Encouraging Clinical Trial Efficacy & Safety Results
Athenex recently announced the presentation of encouraging efficacy and safety data of Oraxol in the treatment of metastatic breast cancer patients who failed previous chemotherapies…
Velesco Pharma Expands, Acquires New Research & cGMP Analytical Laboratory
Velesco Pharma recently announced it has expanded and enhanced its formulation and analytical research and development capabilities with the acquisition of a new facility in…
CytomX Therapeutics Presents Clinical Data From Probody Platform
CytomX Therapeutics, Inc. recently presented clinical results from two arms of the PROCLAIM (PRObody CLinical Assessment In Man) module, PROCLAIM-072. PROCLAIM-072 is an ongoing Phase…
Alcami Helps Medicines Development for Global Health Secure FDA Approval
Alcami Corporation recently announced its collaboration with Medicines Development for Global Health (MDGH), a not-for-profit Australian biopharmaceutical company dedicated to the development of affordable medicines and vaccines for neglected diseases prevalent in low and middle-income countries.
Novel Oral Therapies Could Transform the Standard-of-Care for DME & Lead to Preventative Treatment
Verseon, a technology-based pharmaceutical company, is presently developing multiple novel, small-molecule inhibitors of plasma kallikrein for the treatment of DME. Plasma kallikrein is a central mediator in the kallikrein-kinin system (KKS), a well-known pathway addressing an underlying cause of DME.
VistaGen Therapeutics Acquires Worldwide Rights to Develop & Commercialize First-in-Class Intranasally Administered Drug
VistaGen Therapeutics Inc. recently announced it has exercised its option to acquire from Pherin Pharmaceuticals, Inc. the exclusive license for worldwide rights to develop and commercialize PH10, a first-in-class, intranasally administered neuroactive steroid (a pherine), with rapid-onset antidepressant effects for treatment of major depressive disorder (MDD) demonstrated in a Phase 2a study
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study
VBI Vaccines Inc. recently announced the last subject has received the last vaccination in the PROTECT Phase 3 study of Sci-B-Vac, the company’s third-generation prophylactic hepatitis B vaccine.
Arcis Biotechnology & Teleflex Sign License Agreement
Arcis Biotechnology recently announced it has signed a technology access agreement with Teleflex Incorporated. Teleflex will harness Arcis’ advanced nucleic acid sample preparation chemistry in the development of a novel technology, which it believes will be disruptive, and is intended to empower clinicians and drive better patient outcomes.
Hovione Increases Production Capacity; One-Site-Shop Expands to Respond to Growing Demands
Hovione recently announced a plan to increase production capacity in oral dosage forms in Portugal to strengthen the integrated offering. New commercial-scale equipment for blending, tableting, and coating will complement existing development small-scale equipment.
Principia Achieves $10 Million in Additional Milestones
Principia Biopharma Inc. recently announced the achievement of $10 million in additional milestones related to successful development activities conducted by Principia as part of the…
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ
EyePoint Pharmaceuticals, Inc. recently announced the US FDA has approved YUTIQ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis affecting the posterior segment…
Krystal Biotech Announces Positive Interim Results
Krystal Biotech, Inc. recently announced positive interim results from its ongoing placebo-controlled Phase 1/2 clinical trial of KB103. Two adult Recessive Dystrophic Epidermolysis Bullosa (RDEB),…
Importance of Cell Cycle & Cellular Senescence in the Placenta Discovered
Working with researchers from Stanford University and St. Anna Children's Cancer Research, researchers from Jürgen Pollheimer's laboratory at the Medical University of Vienna's Department of…
Athenex & Xiangxue Life Sciences Announce Preliminary Study Results
Athenex, Inc. recently announced that preliminary results of pilot studies in China in which patients received T-cell receptor affinity enhancing specific T-cell therapy (TAEST) showed encouraging…
Sarepta & Lysogene Announce Exclusive License Agreement
Sarepta Therapeutics, Inc. recently announced it has signed a license agreement with Lysogene (FR0013233475 - LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting…
MeiraGTx Announces Acquisition of Vector Neurosciences
MeiraGTx Holdings Plc recently announced it has acquired Vector Neurosciences Inc. in an all-stock transaction. As a result of the acquisition, which was signed and…
